Genomic Health, TriPath Imaging, Bio-Reference Labs, Canadian Patient Registry

PREDICTIVE TESTING FOR RECURRENT BREAST CANCER LABORATORY TESTS DESIGNED to predict the recurrence of breast cancer are picking up momentum. First to market was Genomic Health Inc.’s Oncotype DX™ breast cancer test. Now TriPath Imaging, Inc. is reporting favorable results from studies of its ProEx Br markers for breast cancer. Since introducing Oncotype DX in […]

To access this post, you must purchase The Dark Report.

Genomic Health, TriPath Imaging, Bio-Reference Labs, Canadian Patient Registry

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month